☰

Dmitri Wiederschain, Ph.D. - Publications

Affiliations: 
2003 Harvard University, Cambridge, MA, United States 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, Winter C, Malkova N, Sun F, Jaworski J, Best A, Pao L, Hebert A, Levit M, Protopopov A, ... ... Wiederschain D, et al. Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. Oncoimmunology. 9: 1811605. PMID 33224628 DOI: 10.1080/2162402X.2020.1811605  0.305
2020 Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R, Theilhaber J, Shehu E, Wu L, Yang ZY, Passe-Coutrin W, Fournier A, Tai YT, Anderson KC, Wiederschain D, et al. Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Frontiers in Immunology. 11: 1771. PMID 32922390 DOI: 10.3389/Fimmu.2020.01771  0.309
2020 Theilhaber J, Pollard J, Pomponio R, Sanicola-Nadel M, Caron A, Naimi S, Wiederschain D, Lin TT, Wang R. Abstract 4321: Integrating multiplex immunohistochemistry (IHC) and transcriptomics for characterization of association between spatial heterogeneity of lymphocytic infiltration and TGFβ pathway activity in solid tumors Endocrinology. 80: 4321-4321. DOI: 10.1158/1538-7445.Am2020-4321  0.319
2018 Wagenaar TR, Hotz C, Gieseke F, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A, Hsu K, Jordan M, Kariko K, Kreiter S, Kuhn AN, Levit M, Malkova N, ... ... Wiederschain D, et al. Abstract LB-130: Combinatorial treatment with intratumoral cytokine mRNAs results in high frequency of tumor rejection and development of anti-tumor immunity across a range of preclinical cancer models Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-130  0.302
2018 Theilhaber J, Cavallo J, Madden SL, Manning C, Cao S, Mankoo P, Pomponio R, Qu H, Malkova N, Shapiro G, Winter C, Wiederschain D, Sanicola-Nadel M, Sun F, Lin TT, et al. Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy Cancer Research. 78: 5550-5550. DOI: 10.1158/1538-7445.Am2018-5550  0.314
2018 Henry C, Lampa M, He T, Ospina B, Zhang B, Deng G, Barberis C, Hoffmann D, Pollard J, Francisco A, Arlt H, Reeves J, Murtie J, Winter C, Richon V, ... ... Wiederschain D, et al. Abstract 5472: Basal-like breast cancer subtype is characterized by deregulated glutamine metabolism and is sensitive to GLS inhibition Cancer Research. 78: 5472-5472. DOI: 10.1158/1538-7445.Am2018-5472  0.314
2017 Lampa M, Arlt H, He T, Ospina B, Reeves J, Zhang B, Murtie J, Deng G, Barberis C, Hoffmann D, Cheng H, Pollard J, Winter C, Richon V, Garcia-Escheverria C, ... ... Wiederschain D, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. Plos One. 12: e0185092. PMID 28950000 DOI: 10.1371/Journal.Pone.0185092  0.349
2015 Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JR, et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 28: 773-84. PMID 26678339 DOI: 10.1016/J.Ccell.2015.11.006  0.302
2015 Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, He T, Shi C, Bedel O, McLean LR, Le-Strat F, Zhang Y, Marquette JP, Gao Q, Zhang B, ... ... Wiederschain D, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. The Journal of Biological Chemistry. 290: 762-74. PMID 25391653 DOI: 10.1074/Jbc.M114.608497  0.326
2014 Huang SM, Wang A, Greco R, Li Z, Barberis C, Tabart M, Patel V, Schio L, Hurley R, Chen B, Cheng H, Lengauer C, Pollard J, Watters J, Garcia-Echeverria C, ... Wiederschain D, et al. Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget. 5: 3362-74. PMID 24830942 DOI: 10.18632/Oncotarget.1951  0.317
2014 Deng G, Licht S, Shen J, Yin M, McManus J, Gee P, He T, Gao G, Zhang B, Mathieu M, Rak A, Bedel O, Shi C, Gross S, Hoffmann D, ... ... Wiederschain D, et al. Abstract 4746: Selective inhibition of mutant IDH1 via small molecule binding to the dimer interface Cancer Research. 74: 4746-4746. DOI: 10.1158/1538-7445.Am2014-4746  0.323
2013 Gao Q, Mechin I, Kothari N, Guo Z, Deng G, Haas K, McManus J, Hoffmann D, Wang A, Wiederschain D, Rocnik J, Czechtizky W, Chen X, McLean L, Arlt H, et al. Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. The Journal of Biological Chemistry. 288: 30125-38. PMID 24003220 DOI: 10.1074/Jbc.M113.473348  0.301
2013 Gao Q, Mechin I, Kothari N, Guo Z, Deng G, Wang A, Wiederschain D, Rocnik J, Czechtizky W, Liu F, Majid T, Patel V, Lengauer C, Garcia-Echeverria C, Zhang B, et al. Abstract 4376: Evaluation of PRP4 kinase as a potential drug target in cancer. Cancer Research. 73: 4376-4376. DOI: 10.1158/1538-7445.Am2013-4376  0.308
2007 Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Research. 67: 6026-30. PMID 17616658 DOI: 10.1158/0008-5472.Can-07-1313  0.663
2007 Kim MM, Wiederschain D, Kennedy D, Hansen E, Yuan ZM. Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP). Oncogene. 26: 4209-15. PMID 17297477 DOI: 10.1038/Sj.Onc.1210212  0.757
2006 Wiederschain D, Yuan ZM. Functional inactivation of P53 as a potential mechanism of MLL leukemogenesis. Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences. 31: 617-20. PMID 17062917  0.665
2005 Wiederschain D, Kawai H, Shilatifard A, Yuan ZM. Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. The Journal of Biological Chemistry. 280: 24315-21. PMID 15851483 DOI: 10.1074/Jbc.M412237200  0.686
2003 Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. DNA damage-induced MDMX degradation is mediated by MDM2. The Journal of Biological Chemistry. 278: 45946-53. PMID 12963717 DOI: 10.1074/Jbc.M308295200  0.657
2003 Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Molecular and Cellular Biology. 23: 4939-47. PMID 12832479 DOI: 10.1128/Mcb.23.14.4939-4947.2003  0.703
2003 Wiederschain D, Kawai H, Gu J, Shilatifard A, Yuan ZM. Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL. Molecular and Cellular Biology. 23: 4230-46. PMID 12773566 DOI: 10.1128/Mcb.23.12.4230-4246.2003  0.7
2002 Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. The Journal of Biological Chemistry. 277: 19251-4. PMID 11953423 DOI: 10.1074/Jbc.C200150200  0.716
2001 Gu J, Nie L, Wiederschain D, Yuan ZM. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Molecular and Cellular Biology. 21: 8533-46. PMID 11713288 DOI: 10.1128/Mcb.21.24.8533-8546.2001  0.708
2001 Kawai H, Nie L, Wiederschain D, Yuan ZM. Dual role of p300 in the regulation of p53 stability. The Journal of Biological Chemistry. 276: 45928-32. PMID 11591713 DOI: 10.1074/Jbc.M107770200  0.693
2001 Wiederschain D, Gu J, Yuan ZM. Evidence for a distinct inhibitory factor in the regulation of p53 functional activity. The Journal of Biological Chemistry. 276: 27999-8005. PMID 11382762 DOI: 10.1074/Jbc.M102400200  0.723
2001 Gu J, Kawai H, Wiederschain D, Yuan ZM. Mechanism of functional inactivation of a Li-Fraumeni syndrome p53 that has a mutation outside of the DNA-binding domain. Cancer Research. 61: 1741-6. PMID 11245491  0.65
2000 LaMontagne KR, Moses MA, Wiederschain D, Mahajan S, Holden J, Ghazizadeh H, Frank DA, Arbiser JL. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. The American Journal of Pathology. 157: 1937-45. PMID 11106566 DOI: 10.1016/S0002-9440(10)64832-8  0.345
2000 Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proceedings of the National Academy of Sciences of the United States of America. 97: 3884-9. PMID 10760260 DOI: 10.1073/Pnas.97.8.3884  0.307
1999 O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. The Journal of Biological Chemistry. 274: 29568-71. PMID 10506224 DOI: 10.1074/Jbc.274.41.29568  0.316
1999 Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, Flynn E, Sytkowski A, Tao T, Langer R. Troponin I is present in human cartilage and inhibits angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 96: 2645-50. PMID 10077564 DOI: 10.1073/Pnas.96.6.2645  0.321
Show low-probability matches.